Prospective Study of Barrier Contraception for the Prevention of Sexually Transmitted Diseases
- 1 March 1999
- journal article
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 26 (3) , 127-136
- https://doi.org/10.1097/00007435-199903000-00002
Abstract
The AIDS epidemic has brought barrier contraceptives to the forefront of public health research. A comprehensive evaluation of the efficacy of barrier contraceptive use in preventing sexually transmitted diseases (STDs), including AIDS, is necessary to inform both potential users and public health policy makers. This study was undertaken to evaluate the efficacy of condoms and vaginal spermicide products, used alone or in combination, in preventing gonorrhea and chlamydia among women attending an STD clinic. To describe the general characteristics of the study group and its follow-up experience. Women who met the eligibility criteria were invited to participate. The initial visit included an interview, a behavioral intervention promoting barrier methods, a physical examination, and instructions to complete a sexual diary. Participants received free barrier contraceptives and returned for six monthly follow-up visits. DESIGN RESULTS: Participants (n = 1,122) were low income, single (74%) black (89%) women with a median age of 24. The behavioral intervention led to the use of barrier protection in more than 70% of reported acts of vaginal intercourse. Barriers were used consistently (100% of sexual acts) during 51% of the months of follow-up. A total of 148 cases of gonorrhea (28 per 1,000 months) and 122 cases of chlamydia infection (23 cases per 1,000 months) were diagnosed during follow-up. This study represents a practical solution to a complex set of design considerations. The study protocol was successful in promoting consistent and proper use of barrier methods.Keywords
This publication has 35 references indexed in Scilit:
- Use of nonoxynol-9 and reduction in rate of gonococcal and chlamydial cervical infectionsThe Lancet, 1992
- In Vitro Evaluations of Condoms with and Without Nonoxynol 9 As Physical and Chemical Barriers Against Chlamydia Trachomatis, Herpes Simplex Virus Type 2, and Human Immunodeficiency VirusSexually Transmitted Diseases, 1989
- A Clinical Trial of Nonoxynol-9 for Preventing Gonococcal and Chlamydial InfectionsThe Journal of Infectious Diseases, 1988
- Condoms as physical and chemical barriers against human immunodeficiency virusJAMA, 1988
- INACTIVATION OF HTLV-III/LAV-INFECTED CULTURES OF NORMAL HUMAN LYMPHOCYTES BY NONOXYNOL-9 IN VITROThe Lancet, 1985
- Efficacy of the Condom as a Barrier to the Transmission of CytomegalovirusThe Journal of Infectious Diseases, 1984
- An ancient method and a modern scourge. The condom as a barrier against herpesJournal of the American Academy of Dermatology, 1983
- Vaginal spermicides and gonorrheaJAMA, 1982
- Infection of the Uterine Cervix with Chlamydia trachomatisThe Journal of Infectious Diseases, 1978
- THE CONDOM AND GONORRHŒAThe Lancet, 1977